Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance

References

• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348:1048–1050.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Lymphoma Myeloma Leuk. 2013;13:515–529.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program. 2009;477–487.
   PubMedGoogle Scholar
• Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009;114:3376–3381.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16:122–131.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011;117:1800–1811.
   PubMed Web of Science ®Google Scholar
• Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the association for molecular pathology. J Mol Diagn. 2009;11:4–11.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Soverini S, De Benedittis C. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor. Am Soc Clin Oncol Educ Book. 2014;34:167–175.
   Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–1215.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26:4806–4813.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol. 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122:872–884. doi:10.1182/blood-2013-05-501569.
   PubMed Web of Science ®Google Scholar
• Alikian M, Gerrard G, Subramanian PG, et al. BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol. 2012;87:298–304.
   PubMed Web of Science ®Google Scholar
• Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–249.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Milojkovic D, Reid AG. Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue – letter. Mol Cancer Ther. 2010;9:2152.
   PubMed Web of Science ®Google Scholar
• Curvo RPM, Zalcberg IR, Scholl V, et al. A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients. Leuk Res. 2008;32:508–510.
   PubMed Web of Science ®Google Scholar
• Laudadio J, Deininger MWN, Mauro MJ, et al. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn. 2008;10:177–180.
   PubMed Web of Science ®Google Scholar
• Sherbenou DW, Hantschel O, Turaga L, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22:1184–1190.
   PubMed Web of Science ®Google Scholar
• Vaidya S, Vundinti BR, Shanmukhaiah C, et al. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor. PLoS One. 2015;10:e0114828.
   PubMed Web of Science ®Google Scholar
• Sakai K, Ishikawa Y, Mori Y, et al. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int J Hematol. 2011;93:237–242.
   PubMed Web of Science ®Google Scholar
• Ernst T, Hoffmann J, Erben P, et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2008;93:1389–1393.
   PubMed Web of Science ®Google Scholar
• Goldman JM. Chronic myeloid leukemia in India. Indian J Med Paediatr Oncol. 2013;34:147–148.
   PubMedGoogle Scholar
• Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10–20.
   PubMed Web of Science ®Google Scholar
• Oehler VG, Qin J, Ramakrishnan R, et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2009;23:396–399.
   PubMed Web of Science ®Google Scholar
• Machova Polakova K, Kulvait V, Benesova A, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141:887–899.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122:1634–1648.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121:489–498.
   PubMed Web of Science ®Google Scholar
• Kagita S, Uppalapati S, Jiwatani S, et al. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol. 2014;35:7187–7193.
   PubMed Web of Science ®Google Scholar
• Gaillard JB, Arnould C, Bravo S, et al. Exon 7 Deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 2010;9:3083–3089.
   PubMed Web of Science ®Google Scholar
• Meggyesi N, Kalmár L, Fekete S, et al. Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. Med Oncol. 2012;29:2136–2142.
   PubMed Web of Science ®Google Scholar
• Cho EH, Kang SK, Kim SY, et al. Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on “A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients” by Curvo. Leuk Res. 2009;33:505–506.
   PubMed Web of Science ®Google Scholar
• Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012;119:1821–1830.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res. 2006;12:7374–7379.
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005–4011.
   PubMed Web of Science ®Google Scholar
• Bengió RM, Riva ME, Moiraghi B, et al. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma. 2011;52:1720–1726.
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen S, Jiang B, et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2011;90:47–52.
   PubMed Web of Science ®Google Scholar
• Elias MH, Baba AA, Azlan H, et al. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-frequency and clinical outcome. Leuk Res. 2014;38:454–459.
   PubMed Web of Science ®Google Scholar
• Wongboonma W, Thongnoppakhun W, Auewarakul CU. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Exp Mol Pathol. 2012;92:259–265.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim D, Kim DW, et al. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol. 2009;27:190–197.
   PubMed Web of Science ®Google Scholar
• Meggyesi N, Kozma A, Halm G, et al. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol. 2012;127:34–42.
   PubMed Web of Science ®Google Scholar
• FE, Nicolini S, Corm QH, Lê, et al., Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia. 2006;20:1061–1066.
   PubMed Web of Science ®Google Scholar
• Markose P, Chendamarai E, Balasubramanian P, et al. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leuk Lymphoma. 2009;50:2092–2095.
   PubMed Web of Science ®Google Scholar